JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

The Journal of the Korean Academy of Child and Adolescent Psychiatry (ISSN: 1225-729X; E-ISSN: 2233-9183) stands as a pivotal resource in the fields of child and adolescent mental health, contributing significantly to the dialogue on psychiatric practices and research in South Korea and beyond. Published by the KOREAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, this journal is recognized for its dedication to advancing the understanding of psychiatric disorders that affect children and adolescents, as evidenced by its Q3 ranking in both Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health categories for 2023. Operated from Seoul, South Korea, the journal facilitates knowledge-sharing among researchers and practitioners, providing insights into clinical practices and innovative treatment methodologies. Although not openly accessible, the journal emphasizes quality over quantity in its selection of studies, making each article a valuable contribution to the field. As the journal continues to publish impactful research through 2024, it remains essential reading for those committed to the well-being of younger populations and their families.

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

Research on Child and Adolescent Psychopathology, with ISSN 2730-7166 and E-ISSN 2730-7174, is a premier academic journal published by Springer, dedicated to advancing the understanding of psychological issues affecting children and adolescents. With an impressive Q1 ranking in both Developmental and Educational Psychology and Psychiatry and Mental Health in 2023, this journal serves as a crucial platform for researchers, practitioners, and students alike, focusing on evidence-based studies, innovative interventions, and the latest trends in child and adolescent mental health. As an Open Access journal, it ensures broader dissemination of knowledge, fostering collaboration and awareness among professionals across disciplines. Rooted in its commitment to tackling critical developmental challenges, Research on Child and Adolescent Psychopathology is not just a publication; it is a vital resource for those dedicated to improving mental health outcomes for young populations in the United States and beyond. Join the conversation as we explore new frontiers in understanding and addressing psychopathological issues.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

Psychiatria i Psychologia Kliniczna - Journal of Psychiatry and Clinical Psychology is a vital platform for advancing the fields of psychiatry and clinical psychology, published by Medical Communications in Poland. With its ISSN 1644-6313, this Open Access journal has been providing unrestricted access to impactful research since 2005, ensuring that findings in mental health are both accessible and disseminated widely. Although currently ranked in the Q4 quartile across Clinical Psychology and Psychiatry and Mental Health categories, and with the Scopus ranks placing it at 262/311 in Clinical Psychology and 493/567 in Psychiatry, the journal serves as a crucial resource for researchers seeking to explore innovative methodologies and therapeutic interventions. The journal's aim is to enhance understanding and treatment of psychiatric disorders by facilitating the exchange of knowledge between academia and clinical practice. As it converges from 2006 to 2024, Psychiatria i Psychologia Kliniczna remains committed to publishing high-quality articles that contribute toward the evolving landscape of mental health research.

The American Journal of Psychiatry, published by the renowned American Psychiatric Publishing, Inc., stands as a premier platform in the field of Psychiatry and Mental Health. With its inaugural edition released in 1945, this esteemed journal has consistently provided a wealth of knowledge, shaping the landscape of psychiatric research and practice globally. Notably, in the latest 2023 Scopus rankings, it achieved an impressive rank of #7 out of 567 journals in its category, placing it in the top 2% percentile, indicative of its substantial impact within the field. The journal is committed to publishing high-quality, peer-reviewed original research, clinical studies, and reviews that advance psychiatric knowledge and treatment options. Although it does not currently offer open access, its contributions are vital for researchers, clinicians, and students dedicated to improving mental health care and understanding complex mental health disorders. As an essential resource, it continues to foster scholarly communication among professionals who are at the forefront of psychiatric science.

Child and Adolescent Psychiatry and Mental Health, published by BMC, is a premier open access journal dedicated to advancing the field of mental health and psychiatric care for children and adolescents. Since its inception in 2007, the journal has fostered a global dialogue among researchers, clinicians, and policy makers by disseminating high-quality research that addresses critical issues in child and adolescent psychiatry. With an impressive Q1 ranking in Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health, it holds a significant position within the academic community, ranking 28th out of 330 in its field. This standing enhances its visibility and relevance, appealing to a wide range of professionals interested in evidence-based practices. As an open access journal, it ensures that research is freely accessible to those who need it most, facilitating greater collaboration and progress. The journal is committed to publishing diverse articles that span various aspects of mental health, including preventive measures, therapeutic interventions, and the intersection of mental health with social determinants. Researchers, practitioners, and students alike will find valuable insights and innovations within its pages, making it an indispensable resource in the field.

PSYCHIATRY AND CLINICAL NEUROSCIENCES is a leading journal in the fields of psychiatry and clinical neurology, published by Wiley. With a commendable impact factor and a position within the prestigious Q1 quartile across multiple relevant categories—including Medicine (Miscellaneous), Neurology, and Psychiatry and Mental Health—this journal stands out for its rigorous peer-reviewed content that addresses critical issues in mental health and neurological disorders. Established in 1933, the journal has a rich history of contributing impactful research that guides both clinical practice and academic inquiry. Although it is not an open-access journal, its high relevance is underscored by its Scopus rankings, with notable percentiles in Psychiatry and Neurology, making it a vital resource for researchers, clinicians, and students looking to stay abreast of the latest advancements. Located in the United Kingdom, PSYCHIATRY AND CLINICAL NEUROSCIENCES aims to bridge the gap between theory and practical application, fostering a comprehensive understanding of the complex interplay between mental health and neurological conditions.